Eli Lilly and Company (LLY.US) Q4 2025 Earnings Conference Call
Live time: Feb 4, 2026 09:00
Eli Lilly and Company (LLY.US) Q4 2025 Earnings Conference Call
Live time: 02/04/2026 09:00:00
礼来公司 (LLY.US) 2025 年第四季度业绩电话会
Summary
00:52
Opening Remarks by Mike Zabar
Mike Zabar, Senior Vice President of Investor Relations, thanks participants for joining Eli Lilly's Q4 2025 earnings call. The session includes prominent executives like CEO Dave Ricks and CFO Lucas Montarce.
02:46
CEO Dave Ricks Q4 Business Overview
CEO Dave Ricks highlights Eli Lilly's strong 2025 growth, reporting a 45% increase in annual revenue and expansion into new markets with key drugs. He emphasizes the company's R&D advancements and production expansions.
05:56
CFO Lucas Montarce Financial Results
CFO Lucas Montarce reports Eli Lilly's robust financial performance in 2025 with $65.2 billion in revenue and a 45% increase year over year. Q4 income improved by 43% due to strong sales of key drugs.
15:07
Dan Skvronsky R&D Developments
Dan Skvronsky, Chief Scientific and Product Officer, discusses significant R&D achievements, including clinical trials for psoriasis and new drug approvals that expand Eli Lilly's product pipeline.
30:02
Evan Seagram from BMO Capital Markets
Responding to Evan's question, the management outlines their focus on market expansion and increased patient satisfaction with Eli Lilly's upcoming products.
33:30
Courtney Breen from Bernstein
Courtney inquires about potential accelerated approval pathways for Eli Lilly's drugs in international markets.
34:00
Chris Schott from JP Morgan
Chris asks about Monjaro's international performance. Management highlights strong Q4 growth and outlines strategies for continued market penetration in 2026.
36:12
Seamus Fernandez from Guggenheim
Seamus queries about Eli Lilly's investments in immunology. The management emphasizes strategic allocations towards immunology and oncology for accelerated growth.
38:31
Terence Flynn from Morgan Stanley
Terence inquires about Medicare growth in 2026. Management remains positive about bringing obesity treatments to Medicare and foresees potential enrollments.
42:04
Geoff Meacham from Citigroup
Geoff queries about combination therapy potentials in INI or oncology, to which the management discusses ongoing trials and strategic priorities for such therapies.
44:13
Asad Haider from Goldman Sachs
Asad asks about pricing dynamics for Eli Lilly’s drug contracts and their impact on market accessibility.
46:41
Mohit Bansal from Wells Fargo
Mohit discusses the importance of obtaining obesity-related indication labels, with management outlining strategies for label expansion and market differentiation.
49:42
Umer Raffat from Evercore
Umer asks about cash-pay dynamic implications. Eli Lilly discusses insights in retaining market share amidst upcoming competition.
51:40
Alex Hammond from Wolfe Research
Alex questions strategies for combining low-dose Olorlin Tide with tirzepatide for effective weight loss solutions.
53:43
James Sinner from Deutsche Bank
James inquires about CMS OBC and similarities to Medicare Part D savings model.
56:48
Steve Scala from TD Cowen
Steve asks if Eli Lilly's revenues can grow without forgoing expectations for orforglume to become a $5 billion product by 2026.
Related Notices
Recent Live Streams
Risk Disclaimer: The content on this page represents the author's personal opinions for general information purposes only and should not be used as a basis for any specific investment, business or commercial decision. It does not represent the position of Longbridge, and the platform makes no guarantees or commitments regarding the authenticity, accuracy or originality of the above content.